Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial

OBJECTIVE: To evaluate the efficacy of covid-19 convalescent plasma to treat patients admitted to hospital for moderate covid-19 disease with or without underlying immunodeficiency (CORIPLASM trial). DESIGN: Open label, randomised clinical trial. SETTING: CORIMUNO-19 cohort (publicly supported platf...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacombe, Karine, Hueso, Thomas, Porcher, Raphael, Mekinian, Arsene, Chiarabini, Thibault, Georgin-Lavialle, Sophie, Ader, Florence, Saison, Julien, Martin-Blondel, Guillaume, De Castro, Nathalie, Bonnet, Fabrice, Cazanave, Charles, Francois, Anne, Morel, Pascal, Hermine, Olivier, Pourcher, Valerie, Michel, Marc, Lescure, Xavier, Soussi, Nora, Brun, Phillipe, Pommeret, Fanny, Sellier, Pierre, Rousset, Stella, Piroth, Lionel, Michot, Jean-Marie, Baron, Gabriel, de Lamballerie, Xavier, Mariette, Xavier, Tharaux, Pierre-Louis, Resche-Rigon, Matthieu, Ravaud, Philippe, Simon, Tabassome, Tiberghien, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619082/
https://www.ncbi.nlm.nih.gov/pubmed/37920150
http://dx.doi.org/10.1136/bmjmed-2022-000427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619082/
https://www.ncbi.nlm.nih.gov/pubmed/37920150
http://dx.doi.org/10.1136/bmjmed-2022-000427

Ejemplares similares